Tests pomegranate juice in adults with ulcerative colitis
Tests daily pomegranate juice in adults with ulcerative colitis, a bowel disease.
Plain-language title generated from the registry record
Registry title: Effects of Pomegranate Juice on Ulcerative Colitis
Key facts
- Where
- Los Angeles, United StatesSee the 2 sites
Where in United States
- UCLA Center for Human NutritionLos Angeles, United StatesTaking people
- West Los Angeles VA Medical CenterLos Angeles, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, Los Angeles
- Trial code
- NCT07115862
- Record updated
- 9 December 2025
- Original description
The purpose of this study is to determine whether consumption of 237 ml of pomegranate juice daily for 8 weeks will:Read full original descriptionShow less
Effect of Pomegranate Juice on Gut Inflammation, Quality of Life and the Gut Microbiome in Patients With Ulcerative Colitis: A Pilot Study
The purpose of this study is to determine whether consumption of 237 ml of pomegranate juice daily for 8 weeks will:
1. lower inflammation (in the gut as well as generally in the body) and improve your overall quality of life 2. affect the microbes living in the gut (gut microbiota)
Inclusion: • Adults ≥ 18 yo; Following a low-polyphenol and fiber diet (< 3 servings of fruits/vegetables per day); Mild-to-moderate UC at the time of screening (2 ≤ partial Mayo scores ≤ 5); Supportive evidence of active inflammation (hsCRP >1 mg/L, fecal calprotectin >50 µg/g stool, or abnormal lower endoscopy) in individuals with biopsy-proven UC; Patients on 5-aminosalicylates must be on a stable dose for ≥ 4 weeks prior to screening; Patients on treatment with immunosuppressive therapy (e.g., azathioprine/6-mercaptopurine, methotrexate) must be on stable dose for 8 weeks prior to baseline visit; At the time of baseline visit, patients may be on no more than 20 mg/day of prednisone and 9 mg/day of budesonide MMX; Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent.
Exclusion: • Non-English speaker; Vegetarian/vegan; Known pomegranate allergy; Documented chronic disease besides UC, including diabetes, renal or liver diseases, metabolic syndrome, active cancer, MI or stroke, history of gastric bypass; Patients with CD, indeterminate/severe to fulminant colitis; History of colectomy or colonic dysplasia; Presence of ileal pouch or ostomy; Evidence of active bacterial or viral gastroenteritis as indicated by positive stool studies for ova \& parasites, Clostridium difficile, and stool culture; Recent hospitalizations (within 2 weeks of screening) for UC requiring IV steroids; Presence of the following labs indicative of severe colitis: a. Hemoglobin < 8.0 g/dl b. Albumin < 3.0 g/dl; Recent systemic antibiotics use (within 3 months of screening) or active use of anti-diarrheal medications; Taking supplements known to affect metabolism or gut microbiota composition (probiotics, fiber, etc.), unless willing to stop for the study duration; Use of Total Parenteral Nutrition (TPN); Use of cyclosporine, tacrolimus, or thalidomide within 2 months prior to screening; Taking exogenous hormones (e.g., hormone replacement therapy); Recent weight fluctuations (>10% in the last 6 months); Smoker or living with a smoker; Use of >20 g of alcohol per day; Unable or unwilling to comply with the study protocol (including unwillingness to avoid watermelon and other lycopene-rich foods for the whole duration of the study); Unable to provide consent.